Audiometry Results and TEOAE and DPOAE Amplitudes in Men Taking a Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction

dc.contributor.authorOntepeli, Sertan
dc.contributor.authorMuluk, Nuray Bayar
dc.contributor.authorTuglu, Devrim
dc.contributor.authorSipal, Timucin
dc.date.accessioned2020-06-25T18:22:54Z
dc.date.available2020-06-25T18:22:54Z
dc.date.issued2017
dc.departmentKırıkkale Üniversitesi
dc.description.abstractWe conducted a prospective study of transient evoked otoacoustic emissions (TEOAEs) and distortion-product otoacoustic emissions (DPOAEs) in men who were taking an oral phosphodiesterase type 5 (PDE5) inhibitor for erectile dysfunction. Our study group was made up of 30 men (60 ears), aged 34 to 60 years (mean: 50.9). They were randomly divided into three groups; 10 men were given sildenafil (Viagra) at 50 mg twice a week, 10 were given tadalafil (Cialis) at 20 mg twice a week, and 10 were given vardenafil (Levitra) at 20 mg twice a week. All patients took their drug for 3 weeks, for a total of 6 tablets for each patient. Audiometric tests and TEOAE and DPOAE measurements were performed before and after treatment. Post-treatment audiometry demonstrated improvement in hearing in all three groups. However, post-treatment TEOAE amplitudes and DPOAE amplitudes differed among the three groups; they were significantly higher in the sildenafil group at 1.0 kHz and the same in the tadalafil group; in the vardenafil group, the DPOAE amplitude was significantly lower at 3.0 kHz while there was no change in the TEOAE amplitude. We speculate that the possible mechanism for these findings is that PDE5 inhibitors block degradation of cyclic guanosine monophosphate (cGMP) and induce dilation of the cochlear microcirculation, resulting in an increase in cochlear blood flow. We also believe that the decrease in DPOAE amplitudes at 3.0 kHz seen in the vardenafil group may be related to an accumulation of nitric oxide/cGMP complex, which is toxic to the cochlea; however, since there was no change in TEOAE amplitude in the vardenafil group, this influence may be minimal. Further studies are needed to obtain a more comprehensive assessment of the effects of PDE5 inhibitors on hearing with the use of higher doses and longer durations of therapy.en_US
dc.description.sponsorshipKirikkale University Scientific Research ProjectKirikkale Universityen_US
dc.description.sponsorshipThis study was conducted with the financial support of the Kirikkale University Scientific Research Project.en_US
dc.identifier.citationÖntepeli S, Muluk NB, Tuğlu D, Şipal T. Audiometry Results and TEOAE and DPOAE Amplitudes in Men Taking a Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction. Ear, Nose & Throat Journal. 2017;96(7):E34-E39.en_US
dc.identifier.doi10.1177/014556131709600707
dc.identifier.endpageE39en_US
dc.identifier.issn0145-5613
dc.identifier.issn1942-7522
dc.identifier.issue7en_US
dc.identifier.pmid28719717
dc.identifier.scopus2-s2.0-85024850992
dc.identifier.scopusqualityQ2
dc.identifier.startpageE34en_US
dc.identifier.urihttps://doi.org/10.1177/014556131709600707
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6951
dc.identifier.volume96en_US
dc.identifier.wosWOS:000471626400004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Incen_US
dc.relation.ispartofEnt-Ear Nose & Throat Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleAudiometry Results and TEOAE and DPOAE Amplitudes in Men Taking a Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunctionen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Audiometry Results and TEOAE and DPOAE Amplitudes in Men Taking a Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction.pdf
Boyut:
689.81 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text